Strategic Alternate options, Conserving Choices Open on THB335


Third Harmonic Bio (THRD) (~$155MM market cap) is a clinical-stage biotech that simply launched information on their Section 1 examine for lead candidate THB335 for the therapy of persistent spontaneous urticaria (hives).  Alongside the announcement (the place the info is seemingly adequate to organize for a Section 2 examine, as standard, no opinion on the science from me), THRD disclosed they have been going to judge a full vary of strategic options and implementing a 50% discount in workforce (eliminating 27 positions).

Persevering with a constructive current pattern, Third Hamonic Bio is doing a lot of the heavy lifting for us, THRD disclosed their estimate for money on 6/30:

Assuming no use of their ATM between 11/1 and at present, I get the next again of the envelope liquidation worth (once more, this possible will not liquidate):

The shareholder base seems to be fairly good right here, Atlas Ventures and OrbiMed Advisors personal collectively about 25% of the corporate, different acquainted names are current in EcoR1 Capital, BVF Companions and RA Capital.  A reverse merger is probably going right here, probably with a CVR connected to THB335.  I added a small place to the rising damaged biotech basket (want some extra momentum in deal bulletins to filter room).

Disclosure: I personal shares of THRD

Leave a Reply

Your email address will not be published. Required fields are marked *